Related Experiment Videos

[Rational diagnosis of hemoptysis]

T M Bauer¹, C T Bolliger, A P Perruchoud

¹Departement Innere Medizin, Universität, Kantonsspital Basel.

Deutsche Medizinische Wochenschrift (1946)

|March 24, 1995

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

See all related articles